Project Grant R43DA064773
- Federal Grant Award Summary SKM Instruments, Inc. received a $314,317 Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop a surface-enhanced Raman spectroscopy (SERS)-based lateral flow assay for rapid detection and quantification of synthetic opioids and emerging psychoactive substances in urine samples. The project, which commenced July 1, 2026, and concludes January 31, 2027, aims to create a portable,...
- Federal Grant Award Summary Taesun, LLC received a $610,738 Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop an integrated fentanyl testing device designed to address critical barriers to accessible drug testing in high-risk environments. The award, initiated August 1, 2025, with a completion date of August 31, 2026, supports the development of a streamlined, all-in-one fentanyl testing device that...
- Federal Project Grant Award Summary LC Acquisition LLC (doing business as Axcend LLC) received a $313,721 Phase I Small Business Innovation Research (SBIR) grant from the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279) for the period June 1, 2026 through May 31, 2027. The award supports the development and evaluation of a miniature tandem Ion Mobility Spectrometry (IMS/IMS) detector designed for integration into the company's commercial Axcend...
- Federal Grant Award Summary Princeton University received a $164,000 Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded August 15, 2025, with completion targeted for July 31, 2027. The award supports development of a Chemical Artificial Intelligence (AI) and Data Science Platform designed to identify and discover novel psychoactive substances (NPS). The project will deliver three primary products: (1) a...
- Federal Grant Award Summary Massachusetts General Hospital's Research Management Division received a $598,000 Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded March 15, 2026, with completion targeted for February 28, 2028. The project delivers advanced machine learning research services to detect emerging overdose trends and identify critical shifts in illicit drug supply patterns. Using restricted National...
- Federal Grant Award Summary Carina Medical LLC received a $304,215 Project Grant from the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279) beginning August 1, 2025 and concluding July 31, 2026. The awardee is developing and validating a novel software platform designed to enable decentralized clinical trials (DCTs) for substance use disorder (SUD) research, with integration of large language models (LLMs). This platform addresses significant...
- Federal Project Grant Award Summary Addinex Technologies, Inc. received a $613,056 Project Grant from the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279) awarded September 1, 2025, with a completion date of August 31, 2026. The grant funds the development and refinement of an adaptive medication adherence and monitoring system designed to support decentralized clinical trials for substance use disorder (SUD) treatment. The deliverable builds upon...
- Federal Cooperative Agreement Summary Award Overview The National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) awarded a $676,305 cooperative agreement to Massachusetts General Hospital (The General Hospital Corporation) for the period of July 1, 2026, through June 30, 2028. The award supports the development and advancement of an inexpensive, wearable functional near-infrared spectroscopy (fNIRS) device—designated the iFLexNIRS—integrated...
- Federal Project Grant Award Summary Tibbling Technologies LLC received a $400,000 Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded June 1, 2026, with a completion date of May 31, 2027. The awardee will develop SmartDrive, an artificial intelligence-powered mobile application designed to detect non-disordered drug use in drivers in real-time before vehicle operation. The cloud-based solution employs a...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded Boston Children's Hospital a $489,500 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) beginning June 1, 2025 and concluding May 31, 2027. This research initiative develops and validates remote oral fluid testing procedures to assess cannabis non-use as a key outcome measure in clinical trials targeting younger adults aged 18-30 years with cannabis use disorder (CUD). The project...
Nefer Ka LLC received a $311,380 Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), effective July 1, 2026 through June 30, 2027. The award supports the development of an economical, portable illicit drug detection system utilizing Surface-Enhanced Raman Scattering (SERS) technology for use in bodily fluid analysis. The project delivers two primary technical innovations: (1) cost-reduced SERS consumable substrates leveraging Nefer Ka's scalable production techniques, which provide enhanced fluorescence quenching to improve signal-to-noise ratio and overall system sensitivity, and (2) investigation and development of a portable Raman spectrometer based on Vertical Waveguide Arrays (VWA) diffraction grating technology that offers improved stability, higher spectral resolution, reduced cost, and programmable grating capability to enable artificial intelligence-controlled data collection. This project addresses a critical gap in drug detection capabilities by providing a target-agnostic approach that can be rapidly adapted to detect novel illicit drugs through electronic protocol distribution, overcoming limitations of conventional testing strips and reducing barriers to deployment compared to centralized laboratory-based instruments. The work is conducted at the awardee's location in Newton, Massachusetts.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $311.4k | 6/23/26 |